Wednesday was one of the rare good days for the beleaguered marijuana industry, with stocks in the sector experiencing significant lifts. One weedie that saw quite the price gain on the day was multistate operator Curaleaf Holdings (CURLF 19.72%), which booked a nearly 20% increase. That compared most favorably to the sleepy S&P 500 index's less than 0.2% improvement.
To a great degree, the future success of Curaleaf and its peers depends on the development of marijuana legalization in this country. At the moment, federal officials are contemplating a proposed rescheduling of the drug, from its most hazardous Schedule I category to the far milder grouping of Schedule III. This would, for all intents and purposes, make the drug legal nationwide.
That potential change seemed to gain significant momentum on Wednesday during a confirmation hearing before the U.S. Senate's Judiciary Committee. President Donald Trump's nominee to lead the Drug Enforcement Administration (DEA), Terrance Cole, stated that reviewing the proposal will be one of his top priorities upon arrival at the DEA, if confirmed by the legislative body.
Although marijuana advocates and cannabis company investors were excited when the proposal was first formally introduced, many have been frustrated by its slow progress up the legal ladder. Cole's remarks indicate that, at the very least, he'll prioritize the matter.
Marijuana company shareholders (and those now contemplating an investment in the sector) should be careful here, though.
Even though Senators from the committee pressed Cole on how he might approach rescheduling, he declined to commit to approving it. He told them that he needs "to understand more where [agencies] are and look at the science behind it and listen to the experts and really understand where they are in the process."
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。